Print

Tesaro, Inc. Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer  
7/23/2013 9:20:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WALTHAM, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), for the treatment of ovarian cancer. This trial, referred to as NOVA, will evaluate a single daily 300 milligram dose of niraparib in 360 patients with high grade serous, platinum sensitive, relapsed ovarian cancer compared to placebo.

Help employers find you! Check out all the jobs and post your resume.

//-->